Nilotinib
- TRADE NAME: Tasigna (Novartis)
- INDICATIONS: Chronic myelogenous leukemia
- CLASS: Antineoplastic / anticancer agent, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 17 hours
Amiodarone, Amitriptyline, Amoxapine, Arsenic, Astemizole, Bepridil, Carbamazepine, Chloroquine, Cisapride, Citalopram, Clarithromycin, Clozapine, Conivaptan, Darunavir, Dasatinib, Degarelix, Delavirdine, Digoxin, Dihydroergotamine, Disopyramide, Dolasetron, Efavirenz, Ergotamine, Grapefruit Juice, Halofantrine, Haloperidol, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Levofloxacin, Lopinavir, Methadone, Midazolam, Moxifloxacin, Oxcarbazepine, Pazopanib, Phenobarbital, Phenytoin, Pimozide, Procainamide, Quinidine, Rifampin, Rifapentine, Ritonavir, Sotalol, St John's Wort, Telavancin, Telithromycin, Terfenadine, Voriconazole, Vorinostat, Ziprasidone
PREGNANCY CATEGORY: D
Contra-indicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of nilotinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/02/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
